tiprankstipranks
Advertisement
Advertisement

SRRK Stock Latest News

Scholar Rock price target raised to $64 from $58 at Wedbush
The FlyScholar Rock price target raised to $64 from $58 at Wedbush
6d ago
SRRK
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance
PremiumThe Fly
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance
6d ago
NVO
SRRK
Scholar Rock price target raised to $63 from $56 at JPMorgan
PremiumThe Fly
Scholar Rock price target raised to $63 from $56 at JPMorgan
10d ago
SRRK
Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status
PremiumThe Fly
Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status
10d ago
SRRK
Scholar Rock Readies for Apitegromab Launch Amid Risks
PremiumCompany Announcements
Scholar Rock Readies for Apitegromab Launch Amid Risks
15d ago
SRRK
Scholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFA
PremiumRatingsScholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFA
18d ago
SRRK
Scholar Rock to remove Catalent Indiana facility from apitegromab BLA
Premium
The Fly
Scholar Rock to remove Catalent Indiana facility from apitegromab BLA
20d ago
NVO
SRRK
Scholar Rock price target raised to $76 from $70 at BMO Capital
Premium
The Fly
Scholar Rock price target raised to $76 from $70 at BMO Capital
20d ago
SRRK
Scholar Rock price target raised to $60 from $58 at Citi
PremiumThe Fly
Scholar Rock price target raised to $60 from $58 at Citi
20d ago
SRRK
Scholar Rock: Buy Rating Reiterated as Apitegromab Advances Toward PDUFA; $65 Price Target Maintained
PremiumRatings
Scholar Rock: Buy Rating Reiterated as Apitegromab Advances Toward PDUFA; $65 Price Target Maintained
20d ago
SRRK
Scholar Rock Expands $200 Million At-The-Market Program
PremiumCompany Announcements
Scholar Rock Expands $200 Million At-The-Market Program
21d ago
8K
SRRK
Scholar Rock reports Q2 EPS (84c), consensus (84c)
PremiumThe Fly
Scholar Rock reports Q2 EPS (84c), consensus (84c)
21d ago
SRRK
Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA
PremiumThe FlyScholar Rock provides update on timing of CHMP opinion for apitegromab MAA
1M ago
NVO
SRRK
Scholar Rock Shareholders Reaffirm Board, Governance and Oversight
Premium
Company Announcements
Scholar Rock Shareholders Reaffirm Board, Governance and Oversight
3M ago
8K
SRRK
Scholar Rock Charts High-Stakes Path to SMA Launch
Premium
Company Announcements
Scholar Rock Charts High-Stakes Path to SMA Launch
3M ago
SRRK
Scholar Rock Charts Path to Apitegromab Approval
PremiumCompany Announcements
Scholar Rock Charts Path to Apitegromab Approval
4M ago
SRRK
JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’
PremiumThe Fly
JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’
4M ago
SRRK
Scholar Rock price target raised to $55 from $53 at Barclays
PremiumThe Fly
Scholar Rock price target raised to $55 from $53 at Barclays
4M ago
SRRK
Scholar Rock price target raised to $65 from $58 at H.C. Wainwright
PremiumThe Fly
Scholar Rock price target raised to $65 from $58 at H.C. Wainwright
4M ago
SRRK
Scholar Rock reports Q1 EPS (83c), consensus (78c)
PremiumThe FlyScholar Rock reports Q1 EPS (83c), consensus (78c)
4M ago
SRRK
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches
Premium
Company Announcements
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches
4M ago
8K
SRRK
Scholar Rock initiated with a Buy at Canaccord
Premium
The Fly
Scholar Rock initiated with a Buy at Canaccord
4M ago
SRRK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >